.

Glyxambi in Real World Indian Type 2 Diabetes Patient (GRID)

Randomized clinical trials (RCTs) have provided evidence for the use of combination therapy with oral anti-diabetic medications i.e. SGLT-2i (Sodium-glucose cotransporter 2 inhibitors) and DPP-4i (Dipeptidyl peptidase-4 inhibitors). Yet, there is a lack of real-world evidence for the same. Kovil and colleagues (2020) have conducted an observational study to provide evidence for the “Effect of Glyxambi in Real World Indian Type 2 Diabetes Patient (GRID)” published in The Journal of the Association of Physician of India. Summary of the studies is provided below: 

Objective:

To generate real-world evidence for glyxambi in the Indian population.

Method:

251 participated patients were followed up for 24 weeks between August 2018 to January 2019. Patients were segregated into four categories as mentioned below, after initiating a fixed-dose combination (FDC) of Empagliflozin and Linagliptin. 

1. Patients naïve to DPP-4i or SGLT-2i use  

2. Patients previously using DPP-4i  

3. Previous users of SGLT-2i 

4. Patients already using SGLT-2i and DPP-4i individually being switched over to the FDC 

Clinical parameters to track changes in glycemia, body weight, and blood pressure are recorded. 

Findings:

As observed in RCTs, real-world use of combination therapy also reported a similar effect. There was an improvement in medication adherence when these two individual agents i.e. Empaglifozin and Linagliptin is replaced by FDC. The study covered a broad range of patients including those using antidiabetic therapy as well as those with comorbid cardiovascular risk. Therefore, the results can be generalized to a broader population for its effectiveness. Additionally, the study also provides insight for benefit of combination therapy in reducing weight and blood pressure. 

Limitation:

Authors acknowledge future studies for combination therapy in relation to the reduction of genitourinary infection. Future real-world studies with a larger sample size might add value to existing evidence as per the researchers.

 

Image Credit: Hand photo created by freepik – www.freepik.com

Afshin Sayyed

Afshin Sayyed joined Zandra Healthcare as an Editor in 2020. She has completed her Bachelor's in Nutrition and Dietetics from SNDT (Shreemati Nathibai Damodar Thackersey Women's) University. She has completed her PG Diploma in Clinical Nutrition and Dietetics from Mumbai University. She is a Certified Diabetes Educator and Content Writer. She has experience in Community Nutrition and other fieldwork with NGO's as well as corporate sectors.

You may also like...